Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 10/20 | 0.63 |
| ▸ | CA1 | P00915 | 10/20 | 0.63 |
| ▸ | CA2 | P00918 | 10/20 | 0.63 |
| ▸ | CA4 | P22748 | 10/20 | 0.63 |
| ▸ | CA7 | P43166 | 10/20 | 0.63 |
| ▸ | CA9 | Q16790 | 10/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | S100A4 | P26447 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6576549 | 1.00 | KMT2A (0.68) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL14349620 | 0.89 | KMT2A (0.55) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL5575433 | 0.89 | TRPV1 (0.66) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL6430735 | 0.88 | CA12 (0.66) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL3263316 | 0.88 | CA12 (0.66) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL1351078 | 0.85 | SYK (0.63) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL1351080 | 0.85 | SYK (0.63) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL13211953 | 0.84 | TRPV1 (0.56) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL13103496 | 0.83 | SYK (0.54) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL14376032 | 0.83 | SYK (0.54) | KMT2ATRPV1TRPM8CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404338-A1 | ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES | Aventis Pharma Deutschland GmbH (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | HERLING ANDREAS (DE) | 2003-09-18 | — | — | US | disclosed |
| EP-0912520-B1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | AVENTIS PHARM PROD INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6559313-B2 | Adenosine derivatives such as (1S,2R,3S,4R)-2,3-dihydroxy-4-(6-(1-(4-trifluormethylpyridin-2-yl)pyrrolidin-3(S)-yl-amino)purin-9-yl)cyclopentanecarboxylic acid isopropylamide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-06 | — | — | US | disclosed |
| WO-2002092093-A1 | ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-21 | — | — | WO | disclosed |
| EP-1258247-A1 | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes | Aventis Pharma Deutschland GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6376472-B1 | N6-SUBSTITUTED ADENOSINES | AVENTIS PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2000023447-A1 | ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC ANTILIPOLYTIC PROPERTIES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0912520-A4 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE POULENC RORER PHARMA (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0912520-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001426-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | IAPP, GPR119, INSR | KMT2A 3621/4885TRPV1 1854/4885TRPM8 2532/4885 |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | HMGCR, TGFB1, APOB | KMT2A 2439/4885TRPV1 1305/4885TRPM8 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.